Adolescent Engagement With a Multicomponent mHealth Tool: Identifying Usage Patterns, Determinants, and Health Behavior Change in an Intervention Trial.
AuteursPeuters C, DeSmet A, Maenhout L, Cardon G, Debeer D, Crombez G
Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives.
AuteursMatos L, van Ramshorst M, Müller V, Agostinetto E, Linn S, Lambertini M, Dieras V, le Du F, Braga S, Criscitiello C, Jerzak KJ, Morgan G, Brucker S, von Kroge P, Haidinger R, Rodríguez Recio G, Schumacher-Wulf E, Fontes Sousa M, Schettini F, Laakmann E
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.
AuteursMatikas A, Naume B, Wildiers H, Sonke G, Dieci MV, Karakatsanis A, Andersson A, Barnekow E, Kessler LE, Einbeigi Z, Killander F, Linderholm B, Schiza A, Valachis A, Nearchou A, Engebraaten O, Porojnicu A, Soland MH, Mannsåker B, Raj SX, Blix ES, Nordstrand CS, Lambertini M, Vernieri C, Punie K, Sotiriou C, Bergh J, Villacampa G, Zouzos A, Hellström M, Hartman J, Foukakis T
Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge.
AuteursGerosa R, Gentile G, Arecco L, Dauccia C, Nannini S, Lobo-Martins S, Agostinetto E, Lambertini M, Santoro A, Aftimos P, Piccart-Gebhart M, de Azambuja E
Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge.
AuteursGerosa R, Gentile G, Arecco L, Dauccia C, Nannini S, Lobo-Martins S, Agostinetto E, Lambertini M, Santoro A, Aftimos P, Piccart-Gebhart M, de Azambuja E
Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge.
AuteursGerosa R, Gentile G, Arecco L, Dauccia C, Nannini S, Lobo-Martins S, Agostinetto E, Lambertini M, Santoro A, Aftimos P, Piccart-Gebhart M, de Azambuja E
